Papaverine hydrochloride - instructions for use, dose, side effects, contraindications

Papaverine hydrochloride lowers the tone of smooth muscles and therefore has a vasodilating and spasmolytic effect. It is an inhibitor of the enzyme phosphodiesterase and causes intracellular accumulation of cyclic 3,5-adenosine monophosphate, which leads to a violation of contractility of smooth muscles and their relaxation during spastic states. The action of papaverine hydrochloride on the central nervous system is poorly expressed, only in large doses, it has some sedative effect.In large doses reduces the excitability of the heart muscle and slows intracardiac conduction.

Pharmacokinetics:

Bioavailability on average - 54%. Connection with blood plasma proteins - 90 %. Easily passes through the histohematological barriers, in the liver undergoes biotransformation. T 1/2 - 0.5 - 2 hours (may extend up to 24 hours). It is excreted by the kidneys mainly in the form of metabolites. Completely removed from the blood during hemodialysis.

Indications:

Spasm of smooth muscles: abdominal cavity organs (cholecystitis, pilorospasm, spastic colitis, renal colic); peripheral vessels (endarteritis); vessels of the brain; heart - angina (as part of complex therapy); bronchospasm. As an auxiliary medicine for premedication.

Contraindications:

Coma; respiratory depression; violation of atrioventricular (AV) conductivity; glaucoma, impaired liver function, age of up to 6 months, elderly age (risk of hyperthermia); hypersensitivity to the drug.

Carefully:

Carefully and in small doses should be prescribed to elderly and weakened patients, as well as patients with craniocerebral trauma,impaired liver and kidney function, hypothyroidism, insufficiency of adrenal function, prostatic hypertrophy, as well as patients with supraventricular tachycardia and those in shock.

Pregnancy and lactation:

In pregnancy and lactation, the safety of the drug is not established.

Dosing and Administration:

The drug is administered intramuscularly, subcutaneously or intravenously. A single dose for adults is 20-40 mg (1 - 2 ml of a solution of 20 mg / ml); the interval between administrations is not less than 4 hours. Intravenous administration is made slowly by diluting the solution of 20 mg / ml of the preparation 10 - 20 ml 0.9 % solution NaCl. For children aged 0.5 to 12 years, the maximum single dose is 0.3 mg / kg body weight.

Side effects:Possible allergic reactions, nausea, constipation, drowsiness, ventricular extrasystole, lowering blood pressure (BP), eosinophilia, increased sweating, AV blockade, increased activity of "liver" transaminases. With rapid intravenous administration, as well as with the use of high doses, it is possible to develop AV blockade, heart rhythm disturbance.

Overdose:Symptoms: impaired vision (double vision), weakness, decreased blood pressure, drowsiness.

Treatment: symptomatic (maintenance of blood pressure).

Interaction:

Papaverin reduces the antiparkinsonian effect of levodopa and the hypotensive effect of methyldopa.

In combination with barbiturates, the spasmolytic effect of papaverine is enhanced.

When combined with tricyclic antidepressants, procainamide, reserpine, quinidine, an increase in the hypotensive effect of papaverine is possible.

Special instructions:

Intravenously, the drug should be administered slowly and under the supervision of a doctor. During the treatment period, alcohol intake should be excluded. In pregnancy and lactation, the safety of the drug is not established.

The vasodilating effect is reduced by smoking.

Effect on the ability to drive transp. cf. and fur:

Papaverine does not affect the ability to drive a car and other working mechanisms.

Form release / dosage:

Solution for injection 20 mg / ml.

Packaging:

2 ml per ampoule.

10 ampoules are placed in a box of cardboard. In each box, an ampoule scaler and instructions for use are attached.

5 ampoules are placed in a contour mesh package made of a polyvinyl chloride film.

2 contour mesh packages together with the instruction for use and the ampoule scarifier are placed in a pack of cardboard.

When using ampoules with a dot or a ring of fracture, the scarifier is not inserted.

Storage conditions:

In the dark place at a temperature of no higher than + 30 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N002111 / 01

Date of registration:26.11.2008

The owner of the registration certificate:MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia

Manufacturer: & nbsp

MOSHIMFARM PREPARATES them. NA Semashko OJSC Russia

Information update date: & nbsp22.08.2015

Illustrated instructions

Instructions

Papaverine hydrochloride (Papaverine hydrochloride)